Levetiracetam Al

Levetiracetam, the active ingredient in Levetiracetam Al, is an anticonvulsant presented as an oral tablet for systemic use. It is employed to control partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy and is approved across the European Union.

GNH USA supplies Levetiracetam Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for import.

Levetiracetam is an antiepileptic medication used to manage seizure disorders.

- Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes. - Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with epilepsy.

Levetiracetam is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Fatigue: increased tiredness or lack of energy. - Somnolence: feeling unusually sleepy. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare skin disorder with blistering. - Blood disorders: leukopenia or thrombocytopenia. - Mood changes: depression or suicidal thoughts. - Rash: widespread or severe dermatologic reactions. - Hepatic dysfunction: abnormal liver enzyme elevations.

Levetiracetam requires careful consideration of patient‑specific factors before use. - Renal impairment: dose may need adjustment based on creatinine clearance. - Hepatic impairment: monitor liver function tests periodically. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Concomitant CNS depressants: may enhance sedation or dizziness. - Mood alterations: monitor for depression or suicidal ideation. - Discontinue abruptly: tapering is recommended to avoid seizure recurrence. - Store at ambient temperature: keep in original container, protect from moisture.

Levetiracetam can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam levels. - Phenytoin: may reduce seizure control by increasing clearance. - Phenobarbital: can diminish therapeutic effect through hepatic induction.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase risk of adverse CNS effects. - Fluconazole: potential for modest increase in levetiracetam concentration. - NSAIDs: monitor for enhanced sedation or dizziness.